Recently, the Efsubaglutide Alfa Injection (trade name: 怡诺轻) of Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. is approved for marketing by China NMPA. This product is indicated for blood glucose control in adult patients with type 2 diabetes.

Efsubaglutide Alfa Injection is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA). It is a recombinant protein formed by the fusion of human glucagon-like peptide-1 (GLP-1) with the Fc fragment of human immunoglobulin G2 (IgG2). This product increases insulin secretion in a glucose-dependent manner and suppresses glucagon release, making it a treatment option for type 2 diabetes. The marketing of this drug provides a new treatment option for relevant patients.